113
Views
16
CrossRef citations to date
0
Altmetric
Review

Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

, , &
Pages 1-10 | Published online: 21 Dec 2018

Abstract

Liver transplantation (LT) is the optimal therapeutic option for patients with liver cirrhosis and hepatocellular carcinoma (HCC). Due to universal donor shortage, only the patients with limited tumor burden (under the so-called Milan criteria) are considered as potential candidates for LT in most institutions. It is expected that in the near future, more liver grafts will be available for patients with HCC due to the implementation of new direct antivirals against hepatitis C, leaving a prone scenario to consider expanding Milan criteria. A moderate expansion of Milan criteria could be implemented without increasing the risk of tumor recurrence if patients with favorable biological behavior are carefully selected. Incorporating information regarding tumor biology in the decision-making algorithm would result in a more rational use of LT in patients with HCC. In the present review, surrogate markers of tumor biology are critically evaluated as potential tools to be combined with existing radiological criteria. In addition, the current state of liquid biopsy is discussed, as this cutting-edge technology may reshape the management of HCC in the upcoming years.

Introduction

Liver transplantation (LT) is the only therapeutic option that is able to cure both hepatocellular carcinoma (HCC) and the underlying liver cirrhosisCitation1 with 5-year survival rates above 70% in most series, which are superior to any other treatment modality.Citation2 However, tumor recurrence may affect up to 15% of patients, and should this complication occur, patients have limited therapeutic options and prognosis may be poor.Citation1 In a setting characterized by donor paucity, it is central to optimize the access to LT. Only the patients with a reduced risk of posttransplant tumor recurrence are granted as potential candidates for LT. The current eligibility criteria for LT are mainly based on tumor burden assessed by dynamic imaging techniques. Most transplant institutions have implemented the so-called Milan criteria:Citation3 a single nodule with a total diameter ≤5 cm, or up to three nodules with a maximum diameter of ≤3 cm each, in the absence of macrovascular invasion or extrahepatic spreading.

Growing evidence supports a moderate expansion of Milan criteria. The upcoming of the new direct antiviral agents against hepatitis C has dramatically decreased the number of patients accessing the waiting lists for LT due to decompensated cirrhosis,Citation2,Citation4 thus leaving more donors available to consider expanding Milan criteria or at least to acknowledge downstaging as a routine approach. Previously proposed strategies consisted in increasing the number and/or diameter of HCC nodules accepted, being the most popular up-to-seven criteria,Citation3 the Clínica Universitaria de Navarra (CUN) criteriaCitation5 and the University of Southern California-San Francisco (UCSF) criteria.Citation6 However, expanding Milan criteria is accompanied by a parallel increase of tumor recurrence rates, leading to the Metroticket principle: the further the ride (in terms of pretransplant tumor burden), the highest the price (in terms of tumor recurrence rates).Citation3

The path toward a more liberal indication of LT in HCC may be walked with leaden feet. A deeper understanding on HCC biology is still needed, and it is central to implement surrogate markers of tumor aggressiveness in clinical practice, in order to ensure that selected patients will remain HCC recurrence-free after LT.Citation7 In the present review, surrogate markers of tumor biological aggressiveness are critically evaluated as potential tools to select candidates for LT, either alone or in combination with existing radiological criteria. In addition, the potential role of liquid biopsy in this clinical scenario is analyzed to delineate future directions.

Serum soluble markers

Tumor burden, as assessed by radiological techniques, is a poor surrogate of HCC biological aggressiveness: large or multiple HCCs are not always associated with aggressive biological behavior and conversely some patients with small uninodular lesions may show histological features indicating an evolved invasive phenotype. Serum proteins produced by the tumor may provide additional information about its biological behavior (). The combination of these biomarkers with radiological assessment may result in a more rational approach to select candidates for LT.Citation8

Table 1 Summary of serum biomarkers with prognostic capacity in patients with hepatocellular carcinoma awaiting liver transplantation

Alpha-fetoprotein (AFP)

AFP is a glycoprotein produced by the liver during fetal life and by a variety of tumors including HCC.Citation9 Serum AFP levels are widely available in clinical practice and they have been traditionally considered a surrogate of tumor burden.Citation10 However, AFP is over-expressed in only 60%–70% of patients with HCC, while false positives may occur in acute and chronic hepatitis from different etiologies.Citation11 As a conse quence, international guidelines have removed serum AFP from the current HCC screening and diagnostic algorithms.Citation1,Citation12 The actual value of serum AFP relies on its prognostic capacityCitation10: increased AFP is associated with histologically poor tumor differentiation, microvascular invasion, increased postoperative tumor recurrence rates and reduced overall survival after LT.Citation13Citation17

A large observational study (n=45,267) showed that patients exceeding Milan criteria had a posttransplant survival comparable to patients who underwent LT for nonmalignant indications if preoperative serum AFP was <15 ng/mL, achieving a 72% 6-year survival rates.Citation18 Unfortunately, such reduced AFP levels are uncommon among patients outside Milan criteria. A higher threshold of AFP <400 ng/mL may be acceptable to rescue more patients exceeding Milan criteria for LT according to two independent observational studies including 2,419 patients.Citation14,Citation19 Indeed, pre-LT AFP ≥400 ng/mL is indicative of poor prognosis, doubling posttransplant recurrence rates as well as dropout from the waiting list due to tumor progression or cancer-related symptoms.Citation14,Citation19Citation22 Moreover, in clinical practice, patients with AFP levels >1,000 ng/mL should be carefully evaluated and LT may be discouraged because of an unacceptable risk of HCC recurrence, even if they fulfill Milan criteria.Citation23,Citation24 In some LT institutions, these patients are evaluated as potential candidates only if AFP decreases below 400 ng/mL after local ablation in a stable fashion.Citation9,Citation25

Des-y-carboxyprothrombin (DCP)

Also known as prothrombin induced by vitamin K absence II (PIVKA-II), DCP is an abnormal form of prothrombin produced predominantly by HCC cells.Citation26 According to a meta-analysis of 12 observational studies, DCP has a modest sensitivity (71%) and specificity (84%)Citation27 for HCC diagnosis,Citation28 which could be improved in combination with other biomarkers such as AFP.Citation29Citation31 Increased DCP also indicates a more aggressive tumor phenotype,Citation30,Citation32 increased microvascular invasion rates,Citation17,Citation33Citation35 extrahepatic metastasesCitation36 and accelerated proliferation.Citation37

DCP may be used to predict disease-free survival and overall survival after LT and is widely used in the Eastern world.Citation38Citation40 DCP >400 mAu/mL at inclusion on the waiting list was associated with a 5-fold increased risk of posttransplant HCC recurrence.Citation41 Unfortunately, these results have not been sufficiently validated. In combination with AFP <300 ng/mL, DCP levels <300 mAU/mL result in 5-year recurrence-free survival rates as high as 70%, provided that total tumor diameter was <10 cm, and in the absence of macrovascular invasion or extrahepatic spreading.Citation42 In Japan, the Kyushu University considered LT in patients with tumors ≤5 cm diameter and serum DCP ≤300 mAU/mL, despite the number of nodules, achieving 5-year overall survival rates of 83%.Citation43 The Kyoto University proposed to restrict the number of nodules (≤10) while increasing the DCP threshold to ≤400 mAU/mL, again with excellent results: 5-year survival rates of 87% and HCC recurrence rates below 3%.Citation44

Inflammatory markers

Neutrophil-to-lymphocyte ratio (NLR),Citation45Citation48 platelet-to-lymphocyte ratio (PLR)Citation49 and, more recently, lymphocyte-to-monocyte ratio (LMR)Citation50 have been proposed as useful biomarkers to predict posttransplant HCC recurrence, overall survival and/or dropout from the waiting list. Reduced baseline NLR was significantly associated with better overall survival (HR =1.80, P<0.00001) and recurrence-free survival (HR =2.23, P<0.00001) after LT, according to a meta-analysis of 90 studies including 20,475 patients.Citation51 Conversely, NLR ≥5 was a significant predictor of poor disease-free survival (HR =19.98, P=0.005) in patients within Milan criteria.Citation45 On the other hand, a high PLR was significantly associated with worse overall survival (HR =1.60, P=0.0005) in a meta-analysis of 10 studies involving 2,315 patients.Citation49 Moreover, a pretransplant PLR ≥125 was associated with significantly more aggressive tumors.Citation52 A more recent study has addressed LMR in LDLT candidates with HCC, showing that a low LMR may be an independent predictor of worse prognosis, particularly among patients beyond the Milan criteria.Citation50

C-reactive protein (CRP) is elevated in many clinical conditions including infections, autoimmune or inflammatory diseases and cancer. In HCC patients, CRP ≥10 mg/dL has been linked with reduced overall survival and recurrence-free survival,Citation53 and it seems to correlate with vascular invasion rates.Citation53Citation56 However, it is unlikely that CRP may become part of therapeutic decisions in HCC patients, either alone or in combination with other biomarkers, given its insufficient specificity.

Other serum markers

The Lens culinaris agglutinin fraction of alpha-fetoprotein (AFP-L3) is a variant of AFP based on the sugar chain structure. AFP-L3 is observed mainly in malignant cellsCitation36 and it correlates with tumor size,Citation57 thus resulting particularly useful in HCC patients who show normal serum AFP. Elevated AFP-L3 was an independent predictor of decreased overall survival and disease-free survival in a meta-analysis of 15 observational studies including 4,465 patients.Citation58 Unlike other biomarkers described above, AFP-L3 is not directly associated with vascular invasion, and its potential role to select candidates for LT remains to be explored.

Osteopontin (OPN) is a protein expressed by transformed malignant epithelial cells from several tumors. It has been suggested as an useful independent diagnostic tool in HCC.Citation59 OPN is over-expressed in advanced tumors, particularly in those with poor histological differentiation,Citation60 and it has been proposed as an independent predictor of tumor recurrence and survival in patients beyond Milan criteria undergoing LT.Citation61 Although promising, optimal thresholds remain to be determined and further validated.

Behavior of the HCC on the waiting list

Dynamic changes in AFP

AFP progressive elevation is a surrogate marker of tumor aggressiveness, foreseeing satellite nodules, vascular invasion and extrahepatic spreading even in small uninodular HCC. As a rule of thumb, dynamic changes in AFP are more reliable than a preoperative single value.Citation18,Citation22 AFP slope >15 ng/mL/month after locoregional ablative therapy (LRT) is an independent predictor of HCC post-LT recurrence,Citation62 and it is associated with decreased overall survival (77% vs 54% at 5 years; P<0.0001)Citation62,Citation63 and recurrence-free survival (74% vs 47% at 5 years; P=0.01).Citation63 There have been several attempts to include AFP as part of a continuous score for patients with HCC awaiting LT. The HCC-MELD score aims to be a continuous score of survival benefit according to liver function and AFP level, calibrated to the survival benefit of non-HCC patients by MELD (for instance, an HCC-MELD score of 20 would calibrate to the survival benefit of a biological MELD score of 20).Citation64 HCC-MELD was designed as a system to give additional, nonarbitrary points based on transplant survival benefit calculation, and it has been independently validated to predict posttransplantation outcome.Citation65 Another variation named deMELD score (where “de” stands for “dropout equivalent”), comprising tumor size, number of nodules and AFP value, aims to provide a dynamic and more accurate assessment of dropout on waiting list.Citation66,Citation67 Further prospective international validation is needed before these scores are implemented in routine clinical practice.

Radiological response to locoregional therapies

The purpose of bridging LRT is to prevent tumor progression and dropout from the waiting list and also to reduce the risk of posttransplant HCC recurrence.Citation68Citation70 Radiofrequency ablation (RFA) and trans-arterial chemoembolization (TACE) are the most frequent modalities of LRT, and there is no definitive evidence that one is superior to the other.Citation71 The use of bridging LRT is highly recommended when the expected length within the waiting list is longer than 6 months,Citation1 but in clinical practice the vast majority of patients undergo LRT unless technically unfeasible.

In this context, the absence of radiological response to LRT is indicative of increased risk of HCC recurrence after LT.Citation68,Citation72,Citation73 Successful downstaging has been associated with excellent posttransplantation outcomes, achieving a 4-year intention-to-treat survival over 92%.Citation74 In a German study assessing TACE for patients awaiting LT (n=50), increased tumor recurrence rates were found in those who showed disease progression despite LRT (64.6% vs 5.5%, P=0.001).Citation75 This is the rationale for the “ablate and wait” strategy, according to which a waiting period of at least 3 months after LRT would be mandatory in order to select those patients with a low risk of recurrence, as a partially treated tumor with favorable biology would not progress in a short observation time.Citation72,Citation74,Citation76Citation78 The increasing evidence regarding this issue led to a recent change of the allocation system in the United States, which now incorporates a 6-month delay before granting MELD exception points in order to identify higher-risk HCC patients.Citation79

Tissue biomarkers

Liver biopsy is not routinely performed for HCC diagnosis in clinical practice due to the precision of dynamic imaging techniques and to the potential risk of biopsy-related complications including tumor seeding.Citation80,Citation81 However, the emerging role of tissue biomarkers to assess tumor biological behavior and to predict response to targeted therapies is changing this scenario.

Vascular invasion is a critical hallmark in HCC spreading, both within and outside the liver, and indicates an evolved tumor phenotype. Microvascular invasion is defined as a tumor emboli within a vascular space (either portal or supra-hepatic), not detectable by radiological techniques, and forms the most reliable predictor of tumor recurrence, able to double the risk after liver resection and triple the risk after LT.Citation82 Unfortunately, microvascular invasion may only be evaluated in the whole HCC specimen and cannot be ruled out by conventional needle biopsy. This fact limits its applicability to select candidates for LT. However, patients who undergo liver resection and show microvascular invasion may be considered for LT, given that tumor recurrence would occur in up to 70% of cases otherwise. There are other classical histological features of HCC related to worse prognosis and able to be detected in a liver biopsy specimen. Moderate– poor tumor differentiation according to the Edmonson scale is associated with more aggressive tumors.Citation3 The group from the University of Toronto considered patients above Milan criteria for LT without any restriction on number/diameter of nodules if poor differentiation is ruled out in a liver biopsy of the dominant nodule.Citation83 In addition, certain HCC histological subtypes such as sarcomatoidCitation84 or macrotrabecularCitation85 are associated with poorly differentiated grades, higher rates of vascular invasion and reduced overall survival.

Glypican-3 (GPC-3) has been identified as a critical tissue marker of HCC.Citation86 It is expressed by more than 90% of AFP-negative tumors,Citation87 while it is not found on cirrhotic and non-cirrhotic adult liver tissues.Citation88 GPC-3 staining pattern, despite not correlating with tumor differentiation,Citation88 is an independent prognostic factor for reduced disease-free survival in patients with HCV infection.Citation89Citation91 Many other biomarkers have been associated with either poorer survival or aggressive tumor behavior,Citation92 including lysosomal protein transmembrane 4 beta-35 (LAPTM4B-35),Citation93 focal adhesion kinase (FAK),Citation94 fascin (FSCN1),Citation95 histone deacetylases,Citation96 CD133,Citation97 nucleophosmin (NPM),Citation98 basic leucine zipper transcription factor ATF-like 2 (BATF2),Citation99 programmed cell death ligands (PDL),Citation100 E-cadherin,Citation101 Dickkopf-1 (DKK1)Citation102,Citation103 and OPN.Citation104,Citation105 However, the true potential of these biomarkers requires further evaluation.

18FDG-Positron emission tomography (PET)

Liver tissue highlighted byCitation18 FDG displays poor grades of differentiation (RR =9.5) and microvascular invasion (RR =6.4).Citation106,Citation107 A positiveCitation18 FDG-PET has been significantly associated with higher risk of post-LT recurrence (HR =3.95, P=0.024) as well as reduced disease-free survival (87% vs 57% at 3 years, P<0.001).Citation108Citation110 In addition, patients outside Milan criteria with a negative PET showed no statistically significant differences in terms of 5-year recurrence-free survival rates when compared to patients within Milan criteria (81% vs 86.2%, P=0.002),Citation111 while a PET positive became an independent predictor of dropout from the waiting list (HR =5.7, P=0.01), providing additional information to elevated serum AFP.Citation112

Liquid biopsy

The detection of tumor byproducts in the bloodstream, also known as liquid biopsy, is a rapidly evolving research field that has engaged the scientific community in recent years. Indeed, identifying circulating-tumor-cells (CTC)Citation113 or cell-free DNAs (cfDNA)Citation114 in the peripheral circulation is a noninvasive and reproducible procedure that could potentially provide dynamic information regarding tumor activity.Citation115Citation118 The quantitative and qualitative assessment of circulating tumor-derived products is attractive as a research field, not only for screening or diagnosis, but also to select candidates for LT and prioritize them within the waiting list.

Circulating tumor cells

HCC recurrence after LT implies that remnant tumor cells are left behind after surgery and remain in the bloodstream unnoticed to the surveillance of the immune system (which is impaired by the use of immunosuppressive drugs).Citation119 The assessment of CTCs before LT is an appealing research field with a huge translational potential. Theoretically, patients with persistently increased number of CTCs despite LRT would be removed from the waiting list and offered alternative therapies, and conversely patients with a complete clearance of CTCs after LRT would be perfect candidates to be included within the waiting list and further prioritized irrespective of their tumor burden.

CTCs have been extensively evaluated in different types of cancer. In order to be implemented in HCC clinical practice, detection techniques of CTCs may be sufficiently accurate, reproducible, affordable and without any significant intra- and interobserver variability.Citation120 In addition, it would be highly desirable that the methodology would allow for an effective recovery of viable CTCs for their ulterior characterization and culture. However, CTCs are scarce in peripheral blood, lost into millions of leukocytes and erythrocytes, thus hampering their identification by using conventional flow cytometry. There is no perfect method for CTCs detection, and usually several technologies are combined to counteract each other disadvantages.Citation120Citation122 Two assays have emerged and launched into the market with some supporting clinical evidence for identification, isolation and enumeration of CTCs in HCC, namely, CellSearch® (Veridex Inc.), which is the only one approved by the FDA, and Isoflux (Fluxion Biosciences), which claims for an improved sensitivityCitation123 and isolation capacity. Both technologies are based on the detection of epithelial cellular adhesion molecule (EpCAM) positive/CD45 negative (EpCAM+/CD45) cells. EpCAM is a transmembrane glycoprotein that is present in epithelial cells and in some types of cancer cells, including HCC.Citation124 In the tumoral tissue, EpCAM+ cells have been correlated with vascular invasion, multinodular tumors and reduced overall survival,Citation113,Citation125,Citation126 being more frequent in the tumor invasion edge. In the bloodstream, CTCs are much increased in patients with microvascular invasion, macrovascular invasion and multinodular diseaseCitation126 leading to poor overall survival.Citation127,Citation128 Persistence of CTCs after liver resection has been associated with early HCC recurrence by using the CellSearch System®: a CTCs ≥2 count was identified as an independent prognostic factor in multivariate analysis, even in subgroups with normal AFP and low-risk histological features.Citation129 Similar findings have been reproduced by other research groups but without an agreement on the optimal threshold of CTCs to predict tumor recurrence.Citation118,Citation130Citation132 A CTCs count slope is also associated with disease progression,Citation133 and the persistence of CTCs after a potentially curative therapy may be an independent prognostic factor.Citation134,Citation135 In patients undergoing LT, an independent association between recurrence-free survival after LT and preoperative CTCs count was demonstrated.Citation136 Even in patients with low AFP levels, CTCs count still predicted outstanding recurrence rates.Citation136 Nevertheless, no significant association was observed between HCC recurrence after LT and total CTCs change or CTCs subtype in another study,Citation137 probably related to its insufficient statistical power due to the small sample size.

A number of issues remain to be solved before implementing CTCs as a biological marker in HCC patients undergoing LT: 1) different methodologies to detect CTCs may be compared face to face in order to identify the most accurate to become the gold standard; 2) an automated methodology for CTC counting may be implemented to reduce interobserver variability while decreasing enumeration length and 3) new prospective, multicenter and well-designed studies need to be conducted in LT candidates and further independently validated.

Cell-free DNA

Detection of cfDNA is another modality of liquid biopsy that is associated with tumor burden, microvascular invasion and extrahepatic metastasis,Citation138Citation140 thus identifying disease progression even in cases of negative AFP. It has been shown to be a highly specific biomarker,Citation141,Citation142 more frequently detected in patients with larger tumors, poor histological differentiation and associated with reduced overall survival as well as early tumor recurrence after curative resection.Citation143Citation145 Moreover, cfDNA allows to analyze HCC genetic and epigenetic profile,Citation146 as it resembles the matched primary tumor.Citation140 cfDNA is also easier to obtain after LRT, and its quantification mirrors radiological response as well as disease progression.Citation139

However, HCC may suffer heterogenous molecular transformations, even in the presence of similar histopathological findings,Citation147 which would make it unlikely to identify every relevant mutation in a single blood sample.Citation148 Targeted deep sequencing may allow to circumvent intratumor heterogeneity,Citation149 identifying mutations which could act as new therapeutic targets. The expression or absence of cfDNA related to EpCAM and AFP defined up to four HCC subtypes, each one displaying distinct tumor features and reflecting different hepatic lineages, being EpCAM+/AFP tumors significantly correlated with lower rates of portal vein invasion and improved overall prognosis. Conversely, tumors with cfDNA encoding AFP were linked to worse prognosis.Citation124 These findings are mainly exploratory but they may impact the decision-making algorithm in the future.

Conclusion

Selected patients outside Milan criteria but showing favorable tumor behavior may be acceptable candidates for LT. Surrogate markers of tumor biology are able to predict outcomes after LT and may be incorporated as part of the decision-making algorithm. Among them, only serum AFP is sufficiently validated to make practical recommendations. Raising AFP over 400 ng/mL despite LRT should motivate a deep evaluation of tumor burden before including a patient in the waiting list. If AFP persists >1,000 ng/mL, LT should be discouraged, even in patients within Milan criteria. There are other serum biomarkers such as DCP, AFP-L3 and NLR, which are already standardized and available in clinical practice, but they deserve further validation to define thresholds and to validate their accuracy before being implemented. Tissue biomarkers are hampered by the need of pre-LT liver biopsy, which is not routinely performed. Liquid biopsy allows detecting and enumerating CTCs, and even to analyze DNA mutations, thus offering direct and dynamic information concerning tumor biological behavior. Although there are still some technical caveats to be solved, liquid biopsy will probably reshape the management of HCC in the upcoming years.

Disclosure

The authors report no conflicts of interest in this work.

References

  • European Association for the Study of the LiverElectronic address: [email protected]; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinomaJ Hepatol201869118223629628281
  • European Association for the Study of the LiverElectronic address: [email protected]. EASL Clinical Practice Guidelines: liver transplantationJ Hepatol201664243348526597456
  • MazzaferroVLlovetJMMiceliRPredicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysisLancet Oncol2009101354319058754
  • European Association for the Study of the LiverElectronic address: [email protected], European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018J Hepatol201869246151129650333
  • HerreroJISangroBPardoFLiver transplantation in patients with hepatocellular carcinoma across Milan criteriaLiver Transpl200814327227818306328
  • YaoFYFerrellLBassNMLiver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survivalHepatology20013361394140311391528
  • Guerrero-MisasMRodríguez-PerálvarezMde La MataMStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationWorld J Hepatol20157464966125866602
  • TsuchiyaNSawadaYEndoISaitoKUemuraYNakatsuraTBiomarkers for the early diagnosis of hepatocellular carcinomaWorld J Gastroenterol20152137105731058326457017
  • CharrièreBMaulatCSucBMuscariFContribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinomaWorld J Hepatol201682188189027478538
  • ChanSLMoFKJohnsonPJNew utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapyJ Clin Oncol200927344645219064965
  • JohnsonPJThe role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinomaClin Liver Dis20015114515911218912
  • BruixJShermanMAmerican association for the study of liver diseasesManagement of hepatocellular carcinoma: an updateHepatology20115331020102221374666
  • TosoCAsthanaSBigamDLShapiroAMKnetemanNMReassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients databaseHepatology200949383283819152426
  • MaileyBArtinyanAKhaliliJEvaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancerArch Surg20111461263321242442
  • MuscariFGuinardJPKamarNPeronJMOtalPSucBImpact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinomaWorld J Surg20123681824183122532309
  • MaWJWangHYTengLSCorrelation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomyWorld J Surg Oncol20131121223981851
  • YamashitaYIImaiKYusaTMicrovascular invasion of single small hepatocellular carcinoma ≤3 cm: predictors and optimal treatmentsAnn Gastroenterol Surg20182319720329863190
  • BerryKIoannouGNSerum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinomaLiver Transpl201319663464523536495
  • TosoCMeebergGHernandez-AlejandroRTotal tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validationHepatology201562115816525777590
  • CiccarelliOLaiQGoffettePLiver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteriaTranspl Int201225886787522716073
  • SapisochinGGoldaracenaNLaurenceJMThe extended Toronto criteria for liver transplantation in patients with hepato-cellular carcinoma: a prospective validation studyHepatology20166462077208827178646
  • LaiQIesariSMelandroFMenniniGRossiMLerutJThe growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolutionTransl Gastroenterol Hepatol201727229034345
  • HameedBMehtaNSapisochinGRobertsJPYaoFYAlpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteriaLiver Transpl201420894595124797281
  • DuvouxCRoudot-ThoravalFDecaensTLiver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteriaGastroenterology2012143498699422750200
  • JangJWYouCRKimCWBenefit of downsizing hepatocellular carcinoma in a liver transplant populationAliment Pharmacol Ther201031341542319821808
  • LiebmanHAFurieBCTongMJDes-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinomaN Engl J Med198431022142714316201741
  • ZhuRYangJXuLDiagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma: a meta-analysisGastroen-terol Res Pract20142014529314
  • XingHYanCChengLClinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinomaTumour Biol2016137121544756
  • SongPFengXZhangKPerspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in ChinaHepatobiliary Surg Nutr20132422723124570947
  • MeguroMMizuguchiTNishidateTPrognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patientsWorld J Gastroenterol201521164933494525945007
  • LimTSKimDYHanKHCombined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patientsScand J Gastroenterol201651334435326340708
  • KimJMHyuckCKwonDProtein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinomaWorld J Surg20133761371137823443153
  • IguchiTShirabeKAishimaSNew pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantationTransplantation20159961236124225427164
  • ShirabeKItohSYoshizumiTThe predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombinJ Surg Oncol200795323524017323337
  • PotéNCauchyFAlbuquerqueMPerformance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasionJ Hepatol201562484885425450201
  • CarrBIKankeFWiseMSatomuraSClinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United StatesDig Dis Sci200752377678217253135
  • MaXLZhuJWuJSignificance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinomaOncol Lett20181568396840429805574
  • TodoSFurukawaHTadaMJapanese Liver Transplantation Study GroupExtending indication: role of living donor liver transplantation for hepatocellular carcinomaLiver Transpl20071311 Suppl 2S48S5417969069
  • ShindohJSugawaraYNagataREvaluation methods for pre-transplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinomaTranspl Int201427439139824472068
  • PommergaardHCBurcharthJRosenbergJRasmussenASerologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysisTransplant Rev (Orlando)201630317117727118303
  • LaiQIesariSLevi SandriGBLerutJDes-gamma-carboxy pro-thrombin in hepatocellular cancer patients waiting for liver transplant: a systematic review and meta-analysisInt J Biol Markers2017324e370e37428561879
  • LeeHWSongGWLeeSGPatient selection by tumor markers in liver transplantation for advanced hepatocellular carcinomaLiver Transpl20182491243125129575509
  • TaketomiASanefujiKSoejimaYImpact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantationTransplantation200987453153719307789
  • TakadaYUemotoSLiver transplantation for hepatocellular carcinoma: the Kyoto experienceJ Hepatobiliary Pancreat Sci201017552753219707711
  • HalazunKJHardyMARanaAANegative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinomaAnn Surg2009250114115119561458
  • LimayeARClarkVSoldevila-PicoCNeutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinomaHepatol Res201343775776423193965
  • XiaoGQLiuCLiuDLYangJYYanLNNeutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantationWorld J Gastroenterol201319458398840724363533
  • LaiQCastro SantaERico JuriJMPinheiroRSLerutJNeutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancerTranspl Int2014271324124118272
  • ZhaoYSiGZhuFPrognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysisOncotarget2017814228542286228206965
  • ManoYYoshizumiTYugawaKLymphocyte-to-monocyte ratio is a predictor of survival after liver transplantation for hepatocellular carcinomaLiver Transpl201824111603161129893464
  • QiXLiJDengHLiHSuCGuoXNeutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: a systematic review and meta-analysis of observational studiesOncotarget2016729452834530127304193
  • XiaWKeQWangYPredictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantationWorld J Surg Oncol2015136025885777
  • ZhengZZhouLGaoSYangZYaoJZhengSPrognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysisInt J Med Sci201310665366423569429
  • AnHJJangJWBaeSHSerum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinomaLiver Transpl201218121406141422821639
  • NaGHKimDGHanJHInflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantationWorld J Gastroenterol201420216594660124914382
  • KimYKKimSHLeeSDHongSKParkSJPretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinomaTransplant Proc201547368669325891712
  • ChoiJYJungSWKimHYDiagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFPWorld J Gastroenterol201319333934623372355
  • ChengJWangWZhangYPrognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysisPLoS One201491e8701124498011
  • WanHGXuHGuYMWangHXuWZuMHComparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysisClin Res Hepatol Gastroenterol201438670671425034355
  • BeckebaumSChenXSotiropoulosGCRole of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resectionTransplant Proc20084093182318419010227
  • SieghartWWangXSchmidKOsteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteriaJ Hepatol2011541899720970216
  • LaiQAvolioAWGraziadeiIAlpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantationLiver Transpl201319101108111823873764
  • VibertEAzoulayDHotiEProgression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factorAm J Transplant201010112913720070666
  • VitaleAVolkMLde FeoTMA method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting listJ Hepatol201460229029724161408
  • GuerriniGPPinelliDMariniEValue of HCC-MELD score in patients with hepatocellular carcinoma undergoing liver transplantationProg Transplant2018281636929251164
  • TosoCDupuis-LozeronEMajnoPA model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting listHepatology201256114915622271250
  • TosoCMajnoPBerneyTMorelPMenthaGCombescureCValidation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting listTranspl Int201427768669524649861
  • CesconMCucchettiARavaioliMPinnaADHepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rateJ Hepatol201358360961823041304
  • ShakerMKMontasserIFSakrMEfficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in EgyptJ Hepatocell Carcinoma20185293629520343
  • ParikhNDWaljeeAKSingalAGDownstaging hepatocellular carcinoma: A systematic review and pooled analysisLiver Transpl20152191142115225981135
  • GyöriGPFelsenreichDMSilberhumerGRSolimanTBerlakovichGAMultimodality locoregional treatment strategies for bridging HCC patients before liver transplantationEur Surg201749523624329104589
  • MazzaferroVSquaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approachHepatology20166351707171726703761
  • PommergaardHCRostvedAAAdamRLocoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant RegistryTranspl Int201831553153929380442
  • YaoFYKerlanRKHiroseRExcellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysisHepatology200848381982718688876
  • OttoGHerberSHeiseMResponse to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinomaLiver Transpl20061281260126716826556
  • RobertsJPVenookAKerlanRYaoFHepatocellular carcinoma: Ablate and wait versus rapid transplantationLiver Transpl201016892592920658555
  • ClavienPALesurtelMBossuytPMRecommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference reportLancet Oncol2012131e112222047762
  • CilloUBurraPMazzaferroVA multistep, consensus-based approach to organ allocation in liver transplantation: toward a “Blended Principle Model”Am J Transplant201515102552256126274338
  • MarvinMRFergusonNCannonRMJonesCMBrockGNMELDEQ: An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinomaLiver Transpl201521561262225694099
  • YuSCLoDYIpCBLiewCTLeungTWLauWYDoes percutaneous liver biopsy of hepatocellular carcinoma cause hematogenous dissemination? An in vivo study with quantitative assay of circulating tumor DNA using methylation-specific real-time polymerase chain reactionAJR Am J Roentgenol2004183238338515269029
  • SilvaMAHegabBHydeCGuoBBuckelsJAMirzaDFNeedle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysisGut200857111592159618669577
  • Rodríguez-PerálvarezMLuongTVAndreanaLMeyerTDhillonAPBurroughsAKA systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variabilityAnn Surg Oncol201320132533923149850
  • DubayDSandroussiCSandhuLLiver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterionAnn Surg2011253116617221294289
  • Martins-FilhoSNPaivaCAzevedoRSAlvesVAFHistological grading of hepatocellular carcinoma-a systematic review of literatureFront Med20174193
  • ZiolMPotéNAmaddeoGMacrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevanceHepatology201868110311229281854
  • JakubovicBDJothySGlypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinomaExp Mol Pathol200782218418917258707
  • ShafizadehNFerrellLDKakarSUtility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrumMod Pathol20082181011101818536657
  • WangHLAnatelliFZhaiQJAdleyBChuangSTYangXJGlypi-can-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesionsArch Pathol Lab Med2008132111723172818976006
  • YoritaKTakahashiNTakaiHPrognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinomaLiver Int201131112013120964802
  • ShirakawaHSuzukiHShimomuraMGlypican-3 expression is correlated with poor prognosis in hepatocellular carcinomaCancer Sci200910081403140719496787
  • LoRCNgIORcLIoNHepatocellular tumors: immunohistochemical analyses for classification and prognosticationChin J Cancer Res201123424525323359751
  • FerrínGAguilar-MeleroPRodríguez-PerálvarezMMontero-ÁlvarezJLde La MataMBiomarkers for hepatocellular carcinoma: diagnostic and therapeutic utilityHepat Med2015711025926760
  • YangHXiongFXLinMYangYNieXZhouRLLAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinomaJ Cancer Res Clin Oncol2010136227528119690886
  • ItohSMaedaTShimadaMRole of expression of focal adhesion kinase in progression of hepatocellular carcinomaClin Cancer Res20041082812281715102689
  • IguchiTAishimaSUmedaKFascin expression in progression and prognosis of hepatocellular carcinomaJ Surg Oncol2009100757557919697358
  • RikimaruTTaketomiAYamashitaYClinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinomaOncology2007721-2697418004079
  • SongWLiHTaoKExpression and clinical significance of the stem cell marker CD133 in hepatocellular carcinomaInt J Clin Pract20086281212121818479363
  • YunJPMiaoJChenGGIncreased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parametersBr J Cancer200796347748417245342
  • MaHLiangXChenYDecreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinomaInt J Cancer2011128477177720473897
  • GaoQWangXYQiuSJOverexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinomaClin Cancer Res200915397197919188168
  • ZhaiBYanHXLiuSQChenLWuMCWangHYReduced expression of E-cadherin/catenin complex in hepatocellular carcinomasWorld J Gastroenterol200814375665567318837082
  • YuBYangXXuYElevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomasJ Hepatol200950594895719303159
  • TungEKMakCKFatimaSClinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinomaLiver Int201131101494150421955977
  • XieHSongJduRPrognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinomaDig Liver Dis200739216717217161983
  • KoritaPVWakaiTShiraiYOverexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinomaHum Pathol200839121777178318701136
  • KornbergAKüpperBThrumKIncreased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patientsTransplant Proc20094162561256319715974
  • CheungTTChanSCHoCLCan positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?Liver Transpl201117101218122521688383
  • YangSHSuhKSLeeHWThe role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patientsLiver Transpl200612111655166016964589
  • LeeJWPaengJCKangKWPrediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinomaJ Nucl Med200950568268719372474
  • LeeSDKimSHKimYK(18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinomaTranspl Int2013261506023106431
  • KornbergAKupperBTannapfelAPatients with non-[18 F] fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantationLiver Transpl20128115361
  • HongGSuhKSSuhSWAlpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantationJ Hepatol201664485285926658686
  • NelIDavidPGerkenGGSchlaakJFHoffmannACRole of circulating tumor cells and cancer stem cells in hepatocellular carcinomaHepatol Int20148332132926202635
  • NgCKYdi CostanzoGGTerraccianoLMPiscuoglioSCirculating cell-free DNA in hepatocellular carcinoma: current insights and outlookFront Med (Lausanne)201857829632864
  • HuangAZhangXZhouSLPlasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinomaJ Cancer20167131798180327698918
  • YinCQYuanCHQuZGuanQChenHWangFBLiquid biopsy of hepatocellular carcinoma: circulating tumor-derived biomarkersDis Markers2016201614278491127403030
  • OkajimaWKomatsuSIchikawaDLiquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acidsWorld J Gastroenterol201723315650566828883691
  • ZhouJHuangAYangXRLiquid biopsy and its potential for management of hepatocellular carcinomaJ Gastrointest Cancer201647215716726969471
  • Rodríguez-PerálvarezMTsochatzisENaveasMCReduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinomaJ Hepatol20135961193119923867318
  • ZhangYLiJCaoLXuWYinZCirculating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectivesSemin Oncol201239444946022846862
  • Paterlini-BréchotPVonaGBréchotCCirculating tumorous cells in patients with hepatocellular carcinoma. Clinical impact and future directionsSemin Cancer Biol200010324124910936072
  • GuoWSunYFShenMNCirculating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinomaClin Cancer Res20182492203221329374055
  • Sánchez-LorencioMIRamirezPSaenzLComparison of two types of liquid biopsies in patients with hepatocellular carcinoma awaiting orthotopic liver transplantationTransplant Proc20154792639264226680058
  • YamashitaTForguesMWangWEpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinomaCancer Res20086851451146118316609
  • NelIBabaHAErtleJIndividual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinomaTransl Oncol20136442042823908685
  • VonaGEstepaLBéroudCImpact of cytomorphological detection of circulating tumor cells in patients with liver cancerHepatology200439379279714999698
  • XuWCaoLChenLIsolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategyClin Cancer Res201117113783379321527564
  • SchulzeKGaschCStauferKPresence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinomaInt J Cancer201313392165217123616258
  • SunYFXuYYangXRCirculating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resectionHepatology20135741458146823175471
  • KelleyRKMagbanuaMJButlerTMCirculating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controlsBMC Cancer20151520625884197
  • RamirezPSáenzLCascales-CamposPAOncological evaluation by positron-emission tomography, circulating tumor cells and alpha fetoprotein in patients with hepatocellular carcinoma on the waiting list for liver transplantationTransplant Proc20164892962296527932119
  • von FeldenJSchulzeKKrechTCirculating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resectionOncotarget2017852899788998729163804
  • GuoWYangXRSunYFClinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platformClin Cancer Res201420184794480525009297
  • FanJLYangYFYuanCHChenHWangFBCirculating tumor cells for predicting the prognostic of patients with hepatocellular carcinoma: a meta analysisCell Physiol Biochem201537262964026344495
  • SunCLiaoWDengZThe diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: a meta-analysisMedicine20179629e751328723763
  • XueFShiSZhangZApplication of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantationOncol Lett20181545481548829552189
  • WangSZhengYLiuJHuoFZhouJAnalysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantationJ Investig Med2018665166
  • HuangZHuaDHuYQuantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinomaPathol Oncol Res201218227127621779787
  • OnoAFujimotoAYamamotoYCirculating tumor DNA analysis for liver cancers and Its usefulness as a liquid biopsyCell Mol Gastroenterol Hepatol20151551653428210698
  • LiaoWYangHXuHNoninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencingOncotarget2016726404814049027248174
  • ChanKCLaiPBMokTSQuantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinomaClin Chem20085491528153618653827
  • DivellaRLacalamitaRTommasiSPAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesisAnticancer Res2008281A22322818383849
  • RenNYeQHQinLXZhangBHLiuYKTangZYCirculating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patientsWorld J Gastroenterol200612243911391416804981
  • TokuhisaYIizukaNSakaidaICirculating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinomaBr J Cancer200797101399140317940509
  • PiciocchiMCardinRVitaleACirculating free DNA in the progression of liver damage to hepatocellular carcinomaHepatol Int2013741050105726202034
  • IkedaSTsigelnyIFSkjevikÅANext-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinomaOncologist201823558659329487225
  • Zucman-RossiJMolecular classification of hepatocellular carcinomaDig Liver Dis201042Suppl 3S235S24120547309
  • PatelASunWMolecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and futureCurr Treat Options Oncol201415338039424838298
  • HuangAZhaoXYangXRCircumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinomaJ Hepatol201767229330128323123